Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ST-601 difluprednate: Phase III data

In 2 double-blind Phase III trials in 439 patients, 0.05% difluprednate (ST-601) met the primary endpoint of

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE